stockrow
Friday 6 November 2026
Export HRTX’s income statement to Excel — free account
Heron Therapeutics, Inc.
HRTX Healthcare Biotechnology
Heron Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $154.9 million, up 7.36% from fiscal 2024.
- Revenue
- +1.25%
- EPS
- −93.6%
- Free cash flow
- +78.8%
- Total debt
- −18.5%
Quarter to June 2026, against a year earlier
0.29
0.01
+3.57%
Follow HRTX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.38 | 1.40 | 1.01 | 0.54 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
161.26 | (23.60) | (98.52) | (36.98) | |
P/B ratio |
30.56 | 16.32 | 18.76 | 13.97 | |
Price to Tangible BV |
30.56 | 16.32 | 18.76 | 13.97 | |
EV/Sales |
1.93 | 2.01 | 1.65 | 1.20 | |
EV/EBITDA |
78.04 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.90) | (11.26) | (12.27) | (15.67) | |
EV/FCF |
(9.63) | (11.17) | (11.95) | (15.04) | |
Quick Ratio |
1.52 | 1.42 | 1.42 | 1.44 | |
Current Ratio |
2.56 | 2.48 | 2.53 | 2.49 | |
Net Debt/EBITDA |
(24.67) | 136.24 | (23.28) | (65.95) | |
Debt/Assets |
56.10% | 54.96% | 57.52% | 56.55% | |
Debt/Equity |
9.38 | 9.81 | 15.50 | 20.65 | |
Asset Turnover |
0.66 | 0.63 | 0.63 | 0.62 | |
Operating CF/Net income |
(0.08) | 3.11 | 0.19 | 0.40 | |
Capex/Depreciation |
0.04 | 0.02 | (0.65) | (0.26) | |
Research and Development Expense of Revenue |
9.08% | 9.23% | 6.87% | 7.17% | |
Selling, General and Administrative Expense of Revenue |
70.45% | 63.28% | 76.21% | 67.53% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.46% | 5.37% | 8.57% | 8.44% | |
Graham Net Nets |
(0.02) | (0.02) | (0.05) | (0.19) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.99%) | (8.88%) | (21.94%) | (44.19%) | |
Free Cash Flow Yield |
(14.46%) | (12.83%) | (13.71%) | (14.77%) | |
Revenue per Share |
0.22 | 0.24 | 0.18 | 0.20 | |
Operating CF per Share |
0.01 | (0.06) | (0.01) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.01 | (0.05) | (0.01) | (0.01) | |
Cash per Share |
0.33 | 0.28 | 0.24 | 0.22 | |
Shareholders Equity per Share |
0.09 | 0.09 | 0.05 | 0.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.09 | 0.09 | 0.05 | 0.04 | |
Free Cash Flow |
1.36 | (9.17) | (1.93) | (2.35) | |
Working Capital |
139.69 | 141.97 | 138.47 | 137.70 | |
Capital Expenditures |
0.03 | 0.02 | (0.39) | (0.14) | |
Net Current Asset Value |
(4.66) | (3.48) | (8.09) | (15.51) | |
EV/EBIT |
187.11 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
134.40 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
74.04 | 84.23 | 81.21 | 84.75 | |
Average Payables |
11.10 | 10.35 | 10.65 | 11.84 | |
Average Inventory |
57.99 | 72.95 | 74.74 | 81.78 | |
Average Assets |
234.86 | 244.51 | 240.98 | 242.18 | |
Average Common Equity |
(16.49) | (10.18) | (10.18) | (10.70) |
Columns are period end dates